Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Total Non-Current Liabilities (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $91.3 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 12.84% to $91.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $91.3 million through Dec 2025, down 12.84% year-over-year, with the annual reading at $91.3 million for FY2025, 12.84% down from the prior year.
  • Total Non-Current Liabilities hit $91.3 million in Q4 2025 for Lyell Immunopharma, up from $76.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $207.0 million in Q2 2021 to a low of $76.2 million in Q3 2025.
  • Historically, Total Non-Current Liabilities has averaged $119.5 million across 5 years, with a median of $93.6 million in 2023.
  • Biggest five-year swings in Total Non-Current Liabilities: tumbled 50.31% in 2023 and later grew 14.62% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $193.1 million in 2021, then tumbled by 48.1% to $100.2 million in 2022, then dropped by 8.77% to $91.4 million in 2023, then rose by 14.62% to $104.8 million in 2024, then fell by 12.84% to $91.3 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for LYEL at $91.3 million in Q4 2025, $76.2 million in Q3 2025, and $83.5 million in Q2 2025.